Merck Gets Canada OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma
January 23 2020 - 8:21AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Thursday said Health Canada approved
its cancer drug Keytruda in combination with Pfizer Inc.'s (PFE)
Inlyta for the first-line treatment of patients with advanced renal
cell carcinoma, the most common type of kidney cancer.
The Kenilworth, N.J., drug maker said the approval is based on a
phase 3 study that showed significant improvements in overall
survival, progression-free survival and objective response rate for
the combination compared with sunitinib.
Keytruda, which was first approved in Canada in 2015, currently
has 14 indications in several disease areas in the country, Merck
said.
Merck last year received U.S. and European Union approval for
the Keytruda/Inlyta combination in advanced renal cell
carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 23, 2020 08:06 ET (13:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024